AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets, AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets, AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets, AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets, AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets, AEGIS, aegis, Aegis, AEGISITN, aegisitn, AEGIS-ITN, aegis-itn,drug discovery, drug development, structure based drug discovery, early stage drug discovery, fragment based drug discovery, PhD program, Doktorandenprogramm, rare disease, neglected disease, Malaria, Leishmania, Chagas disease, Trypanosomia, Tuberculosis, compounds, targets,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.,AEGIS (Accelerated Early staGe drig dIScovery) is an European Marie Sklodowska-Curie Innovative Network program. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on early stage drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on fragment based drug discovery / development. AEGIS (Accelerated Early staGe drig dIScovery) is a scientific research project on structure based drug discovery / development. AEGIS is a doctoral education program. AEGIS is a PhD program. AEGIS bildet Doktoranden aus. AEGIS ist ein Forschungsprojekt auf dem Gebiet der strukturbasierten Wirkstoffforschung. AEGIS will develop active compounds against rare and neglected diseases. AEGIS will develop compounds for Malaria, Leishmania, Chagas disease, Trypanosomia and Tuberculosis.

Skip to main content

Publisher
Helmholtz Zentrum München
Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Ingolstädter Landstraße 1,
D-85764 Neuherberg, Germany
Phone: +49 89 3187-0
website: www.helmholtz-muenchen.de

Representatives
Board of Directors: Prof. Dr. Matthias H. Tschöp, Heinrich Baßler, Dr. Alfons Enhsen
Register of Societies: Amtsgericht München HRB 6466
value added tax identification number: DE 129521671
Chairwoman of Supervisory Board: MinDirig’in Petra Steiner-Hoffmann

Editorial responsibility
Prof. Michael Sattler
Dr. Eva Schlosser


Technical support
Christoph Heidelmann

Photographers

Disclaimer

1. Content

The Helmholtz Zentrum München reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect will therefore be rejected.
Parts of the pages or the complete publication including all offers and information might be extended, changed or partly or completely deleted by the Helmholtz Zentrum München without separate announcement.

2. Referrals and links

The Helmholtz Zentrum München is not responsible for any contents linked or referred to from the Helmholtz Zentrum München´s pages - unless the Helmholtz Zentrum München has full knowledge of illegal contents and is able to prevent the visitors of the Helmholtz Zentrum München site from viewing those pages. If any damage occurs by the use of information presented there, only the author of the respective page might be liable, not the one who has linked to these pages.

3. Copyright

The Helmholtz Zentrum München intended not to use any copyrighted material for the publication or, if not possible, to indicate the copyright of the respective object.

The copyright for any material created by AEGIS is reserved. Any duplication or use of objects such as texts or diagrams, in other electronic or printed publications is not permitted without AEGIS prior agreement (please contact eva.schlosser@helmholtz-muenchen.de).

4. Privacy policy and data protection

If the opportunity for the input of personal or business data (email addresses, name, addresses) is given, the input of these data is voluntary. The use of published postal addresses, telephone or fax numbers and email addresses for marketing purposes is prohibited. Offenders sending unsolicited bulk or commercial email will be held liable.

Only few authorised persons who are involved in the support of the server have access to the data of the web server. In connection with your access to the Helmholtz Zentrum München´s web pages data which may allow identification (e.g. your IP address, date, time and pages visited) are stored on our servers for statistical purposes. The IP address is not used for the identification of the user, and no user profiles which are related to particular individuals or pseudonymised are prepared. We reserve the right to carry out a statistical evaluation of anonymised data records.

5. Legal validity of this disclaimer

This disclaimer is to be regarded as part of the internet publication which you were referred from. If sections or individual terms of this statement are not legal or correct, the content or validity of the other parts remain unaffected by this fact.